Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

BrainsWay Ltd.

BRSYFPNK
Healthcare
Medical - Devices
$11.54
$0.00(0.00%)
U.S. Market opens in 14h 46m

BrainsWay Ltd. Fundamental Analysis

BrainsWay Ltd. (BRSYF) shows moderate financial fundamentals with a PE ratio of 74.61, profit margin of 12.73%, and ROE of 9.46%. The company generates $0.1B in annual revenue with strong year-over-year growth of 29.04%.

Key Strengths

Cash Position16.06%
Current Ratio3.19

Areas of Concern

ROE9.46%
Operating Margin5.78%
PEG Ratio3452.77
We analyze BRSYF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 68.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
68.8/100

We analyze BRSYF's fundamental strength across five key dimensions:

Efficiency Score

Weak

BRSYF struggles to generate sufficient returns from assets.

ROA > 10%
5.53%

Valuation Score

Weak

BRSYF trades at a premium to fair value.

PE < 25
74.61
PEG Ratio < 2
3452.77

Growth Score

Moderate

BRSYF shows steady but slowing expansion.

Revenue Growth > 5%
29.04%
EPS Growth > 10%
1.66%

Financial Health Score

Excellent

BRSYF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.10
Current Ratio > 1
3.19

Profitability Score

Weak

BRSYF struggles to sustain strong margins.

ROE > 15%
9.46%
Net Margin ≥ 15%
12.73%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BRSYF Expensive or Cheap?

P/E Ratio

BRSYF trades at 74.61 times earnings. This suggests a premium valuation.

74.61

PEG Ratio

When adjusting for growth, BRSYF's PEG of 3452.77 indicates potential overvaluation.

3452.77

Price to Book

The market values BrainsWay Ltd. at 6.65 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.65

EV/EBITDA

Enterprise value stands at 59.77 times EBITDA. This signals the market has high growth expectations.

59.77

How Well Does BRSYF Make Money?

Net Profit Margin

For every $100 in sales, BrainsWay Ltd. keeps $12.73 as profit after all expenses.

12.73%

Operating Margin

Core operations generate 5.78 in profit for every $100 in revenue, before interest and taxes.

5.78%

ROE

Management delivers $9.46 in profit for every $100 of shareholder equity.

9.46%

ROA

BrainsWay Ltd. generates $5.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

5.53%

Following the Money - Real Cash Generation

Operating Cash Flow

BrainsWay Ltd. generates strong operating cash flow of $22.94M, reflecting robust business health.

$22.94M

Free Cash Flow

BrainsWay Ltd. generates strong free cash flow of $18.89M, providing ample flexibility for dividends, buybacks, or growth.

$18.89M

FCF Per Share

Each share generates $0.48 in free cash annually.

$0.48

FCF Yield

BRSYF converts 3.81% of its market value into free cash.

3.81%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

74.61

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

3452.77

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.65

vs 25 benchmark

P/S Ratio

Price to sales ratio

9.80

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.19

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.09

vs 25 benchmark

ROA

Return on assets percentage

0.06

vs 25 benchmark

ROCE

Return on capital employed

0.03

vs 25 benchmark

How BRSYF Stacks Against Its Sector Peers

MetricBRSYF ValueSector AveragePerformance
P/E Ratio74.6129.45 Worse (Expensive)
ROE9.46%779.00% Weak
Net Margin12.73%-24930.00% (disorted) Strong
Debt/Equity0.100.26 Strong (Low Leverage)
Current Ratio3.194.65 Strong Liquidity
ROA5.53%-19333.00% (disorted) Weak

BRSYF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BrainsWay Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

4.72%

Industry Style: Defensive, Growth, Innovation

Growing

EPS CAGR

116.68%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

183.84%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ